Grabowska Olga, Martusewicz-Boros Magdalena M, Piotrowska-Kownacka Dorota, Wiatr Elżbieta
Mazovian Center For Treatment of Lung Diseases and Tuberculosis, Otwock, Poland.
3 Lung Diseases Dept., National TB & Lung Diseases Research Institute, Warsaw, Poland.
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):178-181. doi: 10.36141/svdld.v35i2.6554. Epub 2018 Apr 28.
Up to one fourth of sarcoidosis patients may have cardiac involvement, what is potentially a life-threatening condition and requires aggressive treatment. Corticosteroids are generally effective in cardiac sarcoidosis, however may have significant short and long term adverse effects. We present a case of a 42-year-old male, who was diagnosed with pulmonary and cardiac sarcoidosis. He was treated initially with corticosteroids and satisfactory improvement was achieved in the lungs but not in the heart. Methotrexate was added as a second line therapy, being beneficial for the heart as well as steroid sparing agent. Cardiac improvement was documented during serial CMR imaging. .
高达四分之一的结节病患者可能有心脏受累，这可能是一种危及生命的情况，需要积极治疗。皮质类固醇通常对心脏结节病有效，但可能有显著的短期和长期不良反应。我们报告一例42岁男性，被诊断为肺和心脏结节病。他最初接受皮质类固醇治疗，肺部取得了满意的改善，但心脏没有改善。添加甲氨蝶呤作为二线治疗，对心脏有益且可作为类固醇节省剂。在连续的心脏磁共振成像中记录到心脏有所改善。
